Modern cold calling: a case study playbook for healthcare and life sciences in the APAC region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the APAC region. In this market, APAC buyers span very different cultures and reward vendors who adapt playbooks per market, so the way you install modern cold calling has to be shaped to that reality from day one.

Names removed, numbers preserved. This is a real modern cold calling engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.

Week one: diagnosis. The stated problem was "not enough leads". The actual problem was power dialers that torch the list in a week, which had been masked by inbound velocity that peaked two quarters earlier.

Weeks two to three: rebuild the target list from scratch and re-cut the trigger. Modern cold calling works when one connect on the phone beats 40 emails on the right day; the client had drifted away from that first principle.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the APAC region it is compounded by the fact that market-by-market adaptation, not one-size playbooks is what actually gates growth. Modern cold calling is only useful here when it is pointed at both constraints at once.

Weeks four to six: live at 20% of previous volume, quality bar raised. Connects per hour on ICP dials moved every week, though absolute numbers stayed modest.

Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.

What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.

The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.

Concretely for healthcare and life sciences in the APAC region: the healthcare teams that install this get past procurement instead of dying in it, and the APAC teams that install this stop treating the region as one market and start winning it as many. That is the reason it is worth installing modern cold calling deliberately for this market rather than importing a playbook designed for somewhere else.